March 29, 2007 — At the ACC this week Dr. Nabil Dib, M.D., M.Sc., director of Cardiovascular Cell Therapy at University of California San Diego, reported how 23 patients in an FDA trial were safely transformed from advanced heart failure to recovery.
Author and researcher Christian Wilde has spent seven years studying preventive cardiovascular detection and treatment and has worked with Dr. Nabil Dib extensively in preparing his second breakthrough book, “Miracle Stem Cell Heart Repair, www.abigon.com.” This procedure proves for the first time in medical history that dead heart tissue can now be safely clinically repaired. It signifies hope for 22 million patients worldwide currently dying of congestive heart failure.
The book documents case histories and personal journeys of many of Dr. Dib's patients, as well as patients from other ongoing FDA trial successes who have undergone the one time minimally invasive procedure.
Many of Dr. Dib's patients in the trial have had four and even five previous heart attacks, which led them into heart failure. Many also presented with recorded ejection fractions (a measurement of the left ventricle's ability to pump blood) in the very low teens, 20s and 30s. Normal ejection fraction is between 50-70.
Until now, cardiologists have only been able to offer drugs, pacemakers and defibrillators as "band-aids" in treating advancing congestive heart failure. CHF patients may very soon have another promising long-term viable alternative in adult stem cell therapy — cells that the body will not reject and that do not cause tumor development.